A novel stream of brain-penetrant HDAC6 inhibitors

Our R&D programme is focused on our next generation, brain-penetrant, non-hydroxamate, orally-available small molecules, which are being developed for the treatment of glioblastoma, and neurodegenerative and inflammatory disorders, where new biology is emerging.

Research focus

Lead
Design		Lead
Optimization		Pre-clinical
Development
Phase I

Non-hydroxamate, brain-penetrant, HDAC6-targeted inhibitors

Lead Optimisation, Glioblastoma
Lead Design, Neurodegeneration
Lead Design, Inflammatory diseases

Clinical assets for partnering

Lead
Design		Lead
Optimization		Pre-clinical
Development
Phase I

KA2507 – Oral, HDAC6-selective inhibitor

Phase I Monotherapy -Dose Escalation, Solid Tumours (KTP003)

ClinicalTrials.gov Identifier – NCT03008018

KA2237 – Oral, PI3K-p110β/δ-selective inhibitor

Phase I Monotherapy - Dose Escalation, B-cell Lymphomas (KTP002)

ClinicalTrials.gov Identifier – NCT02679196